Candel Therapeutics Q4 operating loss misses analyst expectations

Candel Therapeutics

12/03/2026 12:17

Overview

US cancer immunotherapy developer's Q4 operating loss missed analyst expectations

Q4 net loss widened to $29.5 mln from $14.1 mln a year earlier

Company bolstered cash position with $130 mln loan and $100 mln equity offering

Outlook

Company plans to initiate pivotal phase 3 trial of aglatimagene in NSCLC in Q2 2026

Candel expects to submit BLA for aglatimagene in prostate cancer in Q4 2026

Company says cash position is sufficient to fund operations into Q1 2028

Result Drivers

R&D EXPENSES - Higher research and development costs driven by increased manufacturing, clinical trial and regulatory activities, and employee-related expenses

COMMERCIAL READINESS SPEND - General and administrative expenses rose due to commercial readiness costs, employee-related expenses, and higher professional and consulting fees

Company press release: ID:nGNX3t8psT

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$29.50 mln
Q4 Income From Operations
Miss
-$15.75 mln
-$13.93 mln (6 Analysts)
Q4 Basic EPS
-$0.54
Q4 Operating Expenses
$15.75 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Candel Therapeutics Inc is $16.00, about 213.7% above its March 11 closing price of $5.10

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)